Official Release from Project Sleep Project Sleep is thrilled to announce the official launch of the Sleep Helpline™, a new, professionally-staffed national helpline providing timely and trusted resources to help individuals navigate sleep issues and sleep disorders at every step of the journey. “An estimated 50-70 million Americans live with a chronic […]
Tag: narcolepsy
Jazz Pharmaceuticals Presents Latest Advancements at World Sleep 2023
Jazz Pharmaceuticals plc announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil. The oral presentations include findings from the real-world TENOR study, […]
Promising Results for Narcolepsy Type 1 Treatment, but Safety Concerns Arise
Takeda announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine. These data represent the first-ever clinical data to be published of an oral orexin agonist in NT1. The […]
Sleep Lab Magazine SLEEP 2023 Conference Edition
Sleep Lab Magazine SLEEP 2023 Conference Edition Cover Article Women and Sleep Kin Yuen, MD Feature Articles Sensor Integration: A Paradigm Shift for Oral Appliances Nathan Costiuc, MSN, APRN, FNP-BC Can’t Stop Dreaming: Taylor’s Narcolepsy Story Taylor Dillon Issue Extras SLEEP 2023 Select Exhibitors The Sleep Technologists Behind the V-Com […]
Avadel Pharmaceuticals Receives FDA Approval of Bedtime Narcolepsy Treatment
Avadel Pharmaceuticals plc, announced that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. With final approval, LUMRYZ becomes the […]
Emmanuel Mignot Wins Breakthrough Prize for Discovering Cause of Narcolepsy
Emmanuel Mignot, MD, PhD, the Craig Reynolds Professor of Sleep Medicine, is the winner of a 2023 Breakthrough Prize in Life Sciences. He will share the $3 million prize with Masashi Yanagisawa, MD, PhD, of the University of Tsukuba for discovering the causes of narcolepsy and paving the way for […]
Jazz Pharmaceuticals Presents 18 Abstracts at SLEEP 2021
Jazz Pharmaceuticals plc announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021. “Jazz continues to be committed to deepening our understanding of sleep disorders and delivering […]
FDA Expands Use Of WAKIX For Cataplexy
Harmony Biosciences Holdings, Inc. announced the FDA has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled […]
Jazz Gets FDA Approval of Xywav for Narcolepsy Related Cataplexy or EDS
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with […]
First Non-Scheduled Narcolepsy Treatment Coming Soon
Harmony Biosciences, LLC (Harmony) announced yesterday that FDA approved WAKIX®(pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. WAKIX is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). […]


















